signaling pathway interactions ͉ cAMP ͉ MAP kinase ͉ inhibition of tumor growth C omplex biological processes such as proliferation result from a balance of interactions between signaling pathways. Unregulated cellular proliferation is a defining characteristic of cancer. In the case of cancer of mammary epithelia, progression from the estrogen sensitive to insensitive state and metastasis is accompanied by an increase in expression of several receptor tyrosine kinases, including the epidermal growth factor receptor, erb-B2 or erb-b4 and fibroblast growth factor receptor (1) (2) (3) (4) . Proliferative signals emanating from these tyrosine kinases are generally transmitted through the mitogen-activated protein kinase (MAPK) 1,2 pathway (5, 6). Signal transmission through the MAPK pathway is blocked by elevation of cellular cAMP levels and the consequent protein kinase A effects on c-Raf (7) (8) (9) . Expression of activated G␣ s , which stimulates adenylyl cyclase, blocks Ras-stimulated MAPK activity and Ras-induced transformation of NIH 3T3 cells (4). Activated G␣ s , when expressed in the estrogen-dependent MCF-7 human breast cancer cells, inhibits their ability to form tumors in athymic mice (10) . Elevation of cAMP also induces the cell cycle inhibitor p27kip1 (11) . Decrease in p27kip1 levels is thought to be an important factor in breast tumor progression (12, 13) . p27kip1 associates with active cyclin-dependent kinase (CDK) complexes to inhibit kinase activity and prevent cell cycle progression (14) (15) (16) . Alternatively, the phosphorylation of p27kip1 by the active CDK-2͞cyclin D complex leads to its degradation by proteasome (17, 18) . Increases in cAMP lead to a decrease in CDK-2 activity, and levels of p27kip1 remain elevated. Thus, activated G␣ s may regulate proliferation at multiple sites, which may be advantageous in regulating aggressive proliferative programs in metastatic cells. The growth of these types of tumors cannot be inhibited by anti-estrogens, and generally only nonselective chemotherapeutic agents are therapeutically used. However, with our increasing understanding of how cell proliferation may be inhibited by interactions between signaling pathways, we wondered whether sustained elevation of cAMP in these tumor cells could inhibit tumor growth. Sustained elevation of cAMP may be obtained by expression of mutant (Q227L)-activated G␣ s (G␣* s ; refs. 4 and 10). Hence, we tested whether adenoviral vector-directed expression of Q227L-G␣* s into solid tumors induced by either MDA-435 or MDA-231 cells inhibited tumor growth. Immunoblot Analysis. For MAPK activity and for detection of B-Raf and c-Raf, cells were plated at a density of 10 6 per 10-cm plate. Cells were serum starved 24 h before stimulation by 50 ng͞ml epidermal growth factor (EGF; Upstate Biotechnology). Twelve hours before stimulation with EGF, 1 mM 8Br-cAMP was added to the plates. Control plates were not stimulated with EGF and did not have 8Br-cAMP added to the medium. Five minutes after stimulation, the plates were harvested, electrophoresed, and immunoblotted according to the manufacturer's protocol. For detection of phospho MAPK 1,2 and nonphos-phorylated MAPK 1,2, antibodies were diluted 1:1000 (New England Biolabs). For Raf-B (C-19; Santa Cruz Biotechnology) and c-Raf (C-12; Santa Cruz Biotechnology), the antibodies were diluted at 1 g͞ml. Detection by chemiluminescence was done by using ECL (Amersham Pharmacia) and carried out as described by the manufacturer's protocol. For p27kip1 protein levels, cells were serum starved 24 h before stimulation with serum. Twelve hours before stimulation with serum, 1 mM 8Br-cAMP was added to the plates. Control plates did not have 8Br-cAMP added to the medium. Samples were collected at time 0, 4, 8, and 12 h after stimulation. Immunoblot analysis was performed p27kip1 antibody (1 g͞ml dilution; Upstate Biotechnology).
Methods
Soft Agar Assays. Colony formation in soft agar was used as a measure of anchorage-independent growth, a defining characteristic of transformed cells. For this assay, bottom agar was laid in 60-mm͞gridded dishes (Corning) and contained 0.5% Agar Noble (Difco), DMEM supplemented with 10% FCS containing 100 units͞ml penicillin, 100 g͞ml streptomycin and 500 ng͞ml Fungizone (GIBCO͞BRL). Cells 10 4 were seeded in DMEM supplemented with 10% FCS containing 100 units͞ml penicillin, 100 g͞ml streptomycin, 500 ng͞ml Fungizone, and 0.3% Agar Noble without or with 10 M or 100 M 8Br-cAMP. Plates were fed twice a week, and large colonies were counted after 6 weeks. ). Cells were infected with ADV-G␣* s or ADV-empty (Adenoviral vector) for 12 h before labeling.
Immune Complex CDK2 Kinase Assay. Cells were plated into 10-cm dishes to reach a density of 1 ϫ 10 6 cells per dish the day of the assay. The cells were serum starved 24 h before the assay, and 100 M 8Br-cAMP was added 12-16 h before the start. The cells were then stimulated with 10% FBS and collected at the following time points: 0, 4, 8, and 12 h after stimulation. The assay was carried out as previously described by Matsushime et al. (19) .
Construction, Preparation and Titering of Adenovirus. Adeno-␤-Gal, Adeno-empty vector, and pSKAC were generous gifts from K. Peppel of the Lefkowitz Laboratory (Duke University, Durham, NC). The construction, preparation, and titering was carried out as previously described (20) .
Optimal moi Determined by Transduction by Adeno-␤-Galactosidase.
To determine an optimal moi for transduction by the adenoviral vectors, MDA-231 and MDA-435 were transduced by ADV-␤gal and stained with a 5-bromo-4-chloro-3-indolyl ␤-D-galactoside (X-Gal) solution. MDA-231 and MDA-435 cells were transduced with dilutions of ADV-␤gal ranging from 10 5 -10 Ϫ4 plaque-forming units (pfu) to determine the optimal moi for transduction of the two cell lines. Thirty-six hours after transduction, the cells were washed twice with PBS and fixed in 0.25% glutaraldehyde for 15 min. The plates were then rinsed three times with PBS and incubated with 0.2% X-Gal solution for 1 h at 37°C. The X-Gal solution was then removed, and the plates were covered with 70% glycerol.
Tumorigenesis Experiments. Female athymic mice were purchased from Taconic Laboratories at 2-3 weeks old and were placed in a pathogen-free environment. The mice were allowed to acclimate for a week before being used in studies. 3 , the animals were randomly divided into groups and were injected with vehicle or vehicle containing adenoviral vector. For this procedure, 100 l of PBS, or PBS containing ADV-G␣* s or ADV-␤gal (Ϸ10 9 pfu), was used. This procedure was done every week for 4 weeks. In the second type of experiments, when tumor volume reached 100-200 mm 3 , the animals were randomly divided and were injected with only a single dose of 100 l of PBS, or PBS containing ADV-G␣* s or ADV-␤gal (Ϸ10 9 pfu) at the beginning of the observation period. Tumors size was determined by use of calipers. Growth of tumors was monitored weekly for 5 weeks.
Immunohistochemistry. Tumors were removed 7 days after the last injection and placed in 10%͞formalin͞PBS. The solid tumors were embedded in paraffin and were cut into 5-m sections. Sections were processed for immunocytochemistry with anti␤gal antibody (ICN). Vectastain Elite ABC Kit was used for detection according to the manufacturer's protocol (Vector Laboratories). Tissue sections were counterstained with hematoxylin and eosin.
All experiments were repeated at least three times, and qualitatively similar results were obtained. For animal experiments, the number of animals that was used is shown for each experiment.
Results
We selected two human breast cancer cell lines that represent some of the features found in tumors with advanced stages of the disease. Both MDA-MB-231 and MDA-MB-435 are cell lines that represent later estrogen-independent stages of metastatic breast cancer (21) . MDA-MB-231 cells have high levels of EGF receptors and low levels of erb-B2, whereas MDA-MB-435 have been shown to overexpress erb-B2 (21) (22) (23) (24) . Both receptors have been previously characterized as markers for later stage estrogen-independent mammary tumors (25, 26) . We tested both cell lines for the effects of cAMP on proliferation. For both cell types, when 8Br-cAMP was present, cell proliferation in serum containing medium was substantially inhibited (Fig. 1) .
We analyzed the probable cause(s) for the antiproliferative effects of cAMP on these cell lines. First, we determined the effect of 8Br-cAMP on MAPK 1,2 activation. Serum-starved cells were treated as indicated, and the phosphorylation state of MAPK was measured with phosphoMAPK-1,2-specific antibodies. In the case of MDA-231 cells, 8Br-cAMP, as well as EGF, strongly stimulated MAPK activity. 8Br-cAMP did not inhibit EGF stimulation of MAPK ( Fig. 2A) . The data from the MDA-435 cells was different. Here, 8Br-cAMP by itself stimulated MAPK activity, whereas strongly inhibiting EGF stimulated MAPK activity (Fig. 2B) . These seemingly contradictory results can be explained by the presence of both c-Raf and B-Raf in these cells because c-Raf is inhibited by protein kinase A (PKA) whereas B-Raf is stimulated by the cAMP pathway (27) . Hence, we resolved cellular extracts on SDS͞PAGE and blotted for c-Raf and B-Raf with selective antibodies. Both isoforms were found to be present, and no consistent differences in expression were observed under the varying conditions for both cell lines (Fig. 2 AII and 2BII ). Because 8Br-cAMP substantially inhibited proliferation of both cell types while having differing effects on receptor-tyrosine kinase-stimulated MAPK activity, we looked for other mechanisms by which elevation of cellular cAMP could inhibit proliferation, especially in 231 cells. cAMP is known to trigger the expression of p27kip1, a cyclin-dependent kinase inhibitor, resulting in the inhibition of proliferation (11, 15) . In 231 cells, 8Br-cAMP treatment resulted in elevation of p27kip1 in sustained fashion for 12 h (Fig. 3A) . In contrast, in the absence of 8Br-cAMP, p27kip1 levels are transiently increased on serum stimulation. The sustained elevation p27Kip1 could contribute to the inhibition of CDK2 (28) . Hence, we determined whether CDK2 activity is chronically inhibited in cells treated with 8Br-cAMP. 8Br-cAMP completely suppresses serum-stimulated CDK2 activity in serum-starved cells, although levels of the CDK2 protein do not change (Fig. 3B) . Similar results were obtained for MDA-435 cells as well (Fig. 7 , which is published as supporting information on the PNAS web site, www.pnas.org). These biochemical experiments suggest that the mechanism by which cAMP inhibits proliferation of MDA-231 cells is different from that of MDA-435 cells. In the case of MDA-231 cells, the major locus of action would have to be at the level of p27kip1, which is elevated in a sustained manner because EGF-stimulated MAPK activity is not inhibited by 8Br-cAMP. In contrast, in MDA-435 cells, it appears that the major effect of cAMP may be at the level of the signaling cascade leading to the activation of MAPK 1,2, but induction of p27kip1 could also play a role. On the basis of the biochemical and cell proliferation data, we tested whether 8Br-cAMP could block expression of the transformed phenotype in both cell lines. By using the colony formation in soft agar, we found that the ability of both cell types [MDA-231, Fig. 8A (which is published as supporting information on the PNAS web site); and MDA-435, (10) . To introduce the mutant-activated G␣ s into established tumors in mice, we constructed replication-deficient adenoviral vector containing Q227L-G␣ s (29) . MDA-231 and MDA-435 cells were transduced by ADV-␤gal to determine the optimal moi. An moi of 10 and 200, respectively, were chosen for transduction by ADV-G␣* s or ADV-␤gal as control. These mois were chosen because, at an moi of 10, all MDA-231 cells appeared to be transduced (Fig. 9A , which is published as supporting information on the PNAS web site). At a moi of 100, 30-50% of the MDA-435 cells appeared to be transduced (Fig. 9B) , and, at a moi of 200, 85-95% of the MDA-435 cells were transduced (data not shown). Transduction at these mois significantly raised cAMP levels in both cell types ( Fig. 9 C and D) when compared with nontransduced cells and cells transduced by the empty adenoviral vector (ADV-EMP). We determined the effect of transduction by ADV-G␣* s on the proliferation of MDA-231 and MDA-435 cells. When compared with the nontransduced or cells transduced by ADV-␤-gal, the cells transduced by ADV-G␣* s proliferated very slowly (Fig. 4,  filled circles) . Transduction by ADV-␤gal had some inhibitory effects although the cells were able to maintain their proliferative status (Fig. 4, squares) .
We tested whether expression of G␣* s inhibited the growth of established tumors in vivo. For this test, 10 6 MDA-435 cells or 5-10 ϫ 10 6 MDA-231 cells were injected s.c. into athymic mice, and the tumors were allowed to develop until they reached a tumor volume of 100-200 mm 3 . At this time, ADV-G␣* s , ADV␤gal, or PBS was directly injected into the tumor in a volume of 100 l (Ϸ10 9 infectious particles). Every seventh day, tumors were measured, then the animals were injected with adenoviral vectors or PBS and followed for up to 30 days after the first injection.
We assessed the extent to which the adenoviral vector transduction resulted in expression of the exogenous proteins 7 days after infection. Although we had tagged G␣* s with the FLAG epitope, we were unable to conclusively and reproducibly detect the expression of G␣* s in tissue using the commercially available antibodies by immunohistochemical methods. Hence, we monitored expression by detection of ␤-galactosidase by using an antibody against the enzyme. For this procedure, tumors were excised 7 days after injection of ADV-␤gal, fixed, and embedded in paraffin. Five micrometer cross sections were obtained and then stained with anti-␤gal antibody. Staining with anti-␤gal antibody showed that 55-65% of the tumor sections expressed the ␤-galactosidase protein (Fig. 10 , which is published as supporting information on the PNAS web site). It appeared that, in the periphery, most cells appeared transduced and that the interior did not show any staining for ␤-gal (Fig. 10 Upper) . Control sections showed no background staining with the anti-␤gal antibody (Fig. 10 Lower).
After injections with the adenoviral vectors, we measured tumor growth. For the MDA-231 cells, ADV-G␣* s -injected cells stopped growing completely and showed a small regression (Fig.  5A) . For MDA-231 cells, the ADV-␤gal injections also appeared to slow the growth of tumors, as compared with the PBS-injected tumors (Fig. 5A, middle curve) , although there was substantial growth (doubling of tumor volume in 30 days). We next determined whether multiple injections of ADV-G␣* s are necessary. We injected a single bolus of adenoviral vectors or saline into established tumors and followed tumor growth for the next 4 weeks. A single injection was sufficient to halt tumor growth (Fig. 5B) . We conducted similar experiments with MDA-435 cells. Subcutaneous tumors were formed by injection of cells. PBS or PBS containing ADV-␤gal or ADV-G␣* s was injected when the tumors reached a volume of 100-200 mm 3 . Tumors in animals injected with ADV-G␣* s on a weekly basis stopped growing whereas the tumors in animals injected with PBS or ADV-␤gal nearly quadrupled in sized (Fig. 6A) . For MDA-435 cells as well, a single injection of ADV-G␣* s into tumors blocked further growth (Fig. 6B) . A representative mouse bearing a tumor formed by MDA-435 cells before injections is shown in Fig. 11 A (which is published as supporting information on the PNAS web site). Fig. 11 B and C shows representative mice bearing tumors after treatment with ADV-G␣* s or ADV-␤gal, respectively.
Discussion
Tumor progression is a complex process. In the case of mammary epithelia, there are several characteristics that stand out. One is expression of receptor tyrosine kinases. For some time now, expression of such receptor tyrosine kinases has been viewed as progression markers (25, 26, (30) (31) (32) . That such expression is not merely coincidental but in part causal in the later-stage phenotype is best exemplified by the effects of the erb-b2 antibody in the treatment of the advanced metastatic breast cancer (32) . Another noteworthy characteristic that co-relates with tumor progression is the decrease in the cell cycle inhibitor p27kip1 . Cells were plated into six-well dishes 12 h before vector transduction. Cells were cultured in supplemented DMEM with ADV-␤gal and ADV-G␣* s or without (control). The cells were counted over a period of 7 days. Medium was replenished on day 3. A two-way ANOVA showed that, over the growth period, there was a significant interaction between treatment and cell number for MDA-231 (F 10,36 ϭ 881.14; P Ͻ 0.0001). An ANOVA with Newman-Keuls post hoc test showed that ADV-G␣* streated cells grew to levels significantly different from either ADV-␤gal-treated or control cells on day 4 (F 2,6 ϭ 98.07; P Ͻ 0.001), day 5 (F2,6 ϭ 750.2; P Ͻ 0.001), day 6 (F 2,6 ϭ 735.4; P Ͻ 0.001), and day 7 (F2,6 ϭ 4510; P Ͻ 0.001). A two-way ANOVA showed that, over the growth period, there was a significant interaction between the cell treatment and cell number for MDA-435 (F 10,36 ϭ 73.74; P Ͻ 0.0001). An ANOVA with Newman-Keuls post hoc test ADV-G␣* s-treated cells grew to levels significantly different from either ADV␤gal-treated or control cells on day 2 (F2,6 ϭ10.88; P Ͻ 0.05), day 4 [F2,6 ϭ 11.72; P Ͻ 0.01 (control), P Ͻ 0.05 (␤gal)], day 5 (F2,6 ϭ 7.121; P Ͻ 0.05), day 6 (F2,6 ϭ 14.91; P Ͻ 0.01), and day 7 (F 2,6 ϭ 282.2; P Ͻ 0.001). . Calculated volumes were plotted as percentage change of volume from the initial volume measurements (before injections) were normalized to 100%. The data were analyzed by using a two-way ANOVA, with treatment condition as a between subject factor and time after injection as a repeated factor. There was a significant effect of treatment (F 2,104 ϭ 21.60; P Ͻ 0.0001) and time (F3,104 ϭ 7.71; P Ͻ 0.0001). There was a significant interaction between the treatment and time (F 6,104 ϭ 2.47; P Ͻ 0.03). The data were further analyzed by using Tukey post hoc tests. Mice treated with ADV-G␣* s differed significantly from controls on days 22 (P Ͻ 0.004) and 29 (P Ͻ 0.0001), and on no day was there any significant difference to ␤gal controls. (B) The effect of a single vector injection (arrow) of PBS, ADV-␤gal, and ADV-G␣* s on established tumors of MDA-231. Tumors were measured and injected with a single dose of ADV-G␣* s, ADV-␤gal, or saline and then measured every seventh day for 30 days (indicated by the arrow). Calculated volumes were plotted as percentage change of volume from the initial volume measurements (before injection) were normalized to 100%. The data were analyzed by using a two-way ANOVA, with treatment condition as a between subject factor and time after injection as a repeated factor. There was a significant effect of treatment (F 2,141 ϭ 38.52; P Ͻ 0.0001) and time (F3,141 ϭ 9.99; P Ͻ 0.0001). There was a significant interaction between the treatment and time (F 6,141 ϭ 2.63; P Ͻ 0.02). The data were further analyzed by using Tukey post hoc tests. Mice treated with ADV-G␣* s differed significantly from ␤gal controls on days 15 (P Ͻ 0.03), 22 (P Ͻ 0.0001), and 29 (P Ͻ 0.0001) and differed significantly from PBS controls only on day 29 (P Ͻ 0.001). levels in primary breast tumor tissue (12) . Elevation of cellular cAMP inhibits signal flow from receptor tyrosine kinases to MAPK and stimulates the expression of the cell cycle inhibitor p27kip1 and subsequently decreasing the activity of CDKs. Thus, elevation of cellular cAMP levels in mammary tumors in a sustained manner could be a rational mechanistic approach to block the growth of later stage tumors. Expression of Q227L-G␣ s in the target tissue is a reliable method of constitutively elevating cAMP levels. Our experiments with the adenovirus-directed expression of Q227L-G␣ s in established tumors indicate that this rational approach is successful in blocking tumor growth. This result was not predictable because in vivo other compensatory mechanisms may have easily negated the effects of sustained cAMP elevation. However, it appears that the cAMP-mediated cross-regulation does function in vivo. Hence, induction of sustained interactions between upstream components of different signaling pathways may be a useful approach in regulating the growth of later stage mammary tumors.
Our data and the multiplicity of the sites of action of cAMP suggest that, in different types of mammary tumors, expression of G␣ s could use different mechanisms to inhibit tumor progression. We suggest that, in MDA-231 cells, the biologically relevant cAMP effects are likely to be at the level of p27kip. In contrast, in the MDA-435 cells, the effects are more upstream because elevation of cAMP blocks receptor activation of MAPK. It has been long noted that there several distinct subclasses of later stage breast cancers, as characterized by progression markers such as erb-B2 or EGF receptors (21) (22) (23) (24) (25) (26) . Our functional analysis suggests that there are differences in the organization of the signaling pathways as well. In the MDA-435 cells, the action of c-Raf seems to predominate because cAMP inhibits EGF receptor activation of MAPK. In contrast, in MDA-231 cells, the action of B-Raf appears to predominate because cAMP by itself extensively stimulates MAPK and cAMP does not inhibit tyrosine kinasestimulated MAPK stimulation. Here, inhibition of proliferation appears to be achieved by induction of the cell cycle inhibitor p27kip1 and a decrease in CDK2 activity. Sustained elevation of cAMP acting at multiple sites may be of general value because it is capable of inhibiting the growth of different subclasses of late stage mammary tumors.
Although we could block tumor growth completely, we were unable to obtain tumor regression by expression of G␣ s . This result could be due to two reasons. First, because we only infect the outer layer of the tumor cells, the bystander effect is not sufficiently robust to kill all of the tumor cells. Alternatively, the cells in the tumor are quiescent but not committed to apoptosis and an agent that promotes apoptosis when used in conjunction with expression of G␣* s will cause full tumor regression. The observation of a lack of gross morphological differences between the G␣* s vs. the ␤-gal and vehicle-injected tumors (data not shown) suggests that the later explanation might be correct. These alternatives will have to be definitively resolved by further experiments.
In conclusion these studies show that the interactions between signaling pathways could be a basis for therapy of later stage breast cancers. The development of appropriate small molecule agents targeted to such interaction sites may be therapeutically valuable. Fig. 6. (A) The effect of PBS, ADV-␤gal, and ADV-G␣* s on established tumors of MDA-435 origin in athymic nude mice. Tumors were measured and injected with ADV-G␣* s, ADV-␤gal, or saline every seventh day for 30 days (indicated by arrows). Calculated volumes were plotted as percentage change of volume from the initial volume measurements (before injections) were normalized to 100%. The data were analyzed by using a two-way ANOVA, with treatment condition as a between subject factor and time after injection as a repeated factor. There was a significant effect of treatment (F 2,108 ϭ 17.71; P Ͻ 0.0001) and time (F3,108 ϭ 12.09; P Ͻ 0.0001). There was a significant interaction between the treatment and time (F 6,108 ϭ 307; P Ͻ 0.008). The data were further analyzed by using Tukey post hoc tests. Mice treated with ADV-G␣* s differed significantly from PBS controls on days 22 (P Ͻ 0.05) and 29 (P Ͻ 0.0001) and differed significantly from ␤gal controls only on day 29 (P Ͻ 0.0001). (B) The effect of a single injection (arrow) of PBS, ADV-␤gal, and ADV-G␣* s on preformed tumors of MDA-435. Tumors were measured and injected with a single dose of ADV-G␣* s, ADV-␤gal, or saline and then measured every seventh day for 30 days (indicated by the arrow). Calculated volumes were plotted as percentage change of volume from the initial volume measurements (before injection) were normalized to 100%. The data were analyzed by using a two-way ANOVA, with treatment condition as a between subject factor and time after injection as a repeated factor. There was a significant effect of treatment (F 2,62 ϭ 33.39; P Ͻ 0.0001) and time (F3,62 ϭ 13.92; P Ͻ 0.0001). There was a significant interaction between the treatment and time (F 6,62 ϭ 2.44; P Ͻ 0.035). The data were further analyzed by using Tukey post hoc tests. Mice treated with ADV-G␣* s differed significantly from ␤gal controls on days 22 (P Ͻ 0.005) and 29 (P Ͻ 0.0001) and differed significantly from PBS controls only on day 29 (P Ͻ 0.0035).
